Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone

Documenti analoghi

• Lack of Concentration‐QTc Relationship and Cardiac Risk With Vatiquinone Therapeutic and Supratherapeutic Doses
  di: Lucy Lee, et al.
  Pubblicazione: (2024)
• Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants
  di: Yan‐ou Yang, et al.
  Pubblicazione: (2025)
• Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies
  di: Yingxue Chen, et al.
  Pubblicazione: (2025)
• Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects
  di: Martha Gonzalez, et al.
  Pubblicazione: (2025)
• Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier
  di: Lucy Lee, et al.
  Pubblicazione: (2025)